Jumpmind Announces Strategic Investment from Lone View Capital
15.9.2025 12:00:00 CEST | Business Wire | Press Release
Jumpmind, a leading provider of innovative retail technology solutions, announced today that Lone View Capital (“Lone View”), a growth-oriented private equity firm focused on technology and software investments, has made a strategic investment, acquiring a controlling stake in the company.
Founded in 2008, Jumpmind was recently recognized as a Leader in the Forrester Wave™ for Point of Service Solutions (Q4 2024). The company’s flagship product, Jumpmind Commerce, is a cloud-native, microservices-based point of service platform that enables retailers to unify digital and in-store experiences, streamline checkout, and deliver more personalized customer interactions. Trusted by leading retailers worldwide, the platform supports device independence, rapid deployment, and highly configurable customer journeys – empowering enterprises to adapt quickly in today’s dynamic retail landscape. Jumpmind was named POS Solution of the Year in the 2025 RetailTech Breakthrough Awards.
In addition to its retail commerce platform, Jumpmind offers SymmetricDS and Metl, enterprise-grade tools for real-time data integration and synchronization. Used across industries worldwide, they deliver the resilience needed to keep critical operations running without interruption.
“Jumpmind has established itself as a trusted partner to leading retailers across North America, Europe, and Asia, with a cloud, and hardware agnostic platform that offers a differentiated alternative to legacy systems,” said Doug Ceto, Partner at Lone View Capital. “We are excited to partner with Joe and the Jumpmind team to build on this momentum, expand their reach, and help them grow into the next leader in retail software.”
Following the investment, Jumpmind CEO Joe Corbin will remain in his role and continue guiding the company’s growth.
“Lone View brings deep expertise in software and technology, along with a strong track record of scaling businesses, and we are excited to partner with them,” said Joe Corbin, CEO of Jumpmind. “This investment positions us to accelerate our product roadmap, deepen customer relationships, and continue delivering innovative software that transforms the retail experience.”
ScaleView Partners served as exclusive financial advisor to Jumpmind. Harris Williams served as financial advisor to Lone View. Massumi + Consoli served as legal counsel to Lone View.
About Jumpmind
Jumpmind is a leading provider of innovative retail technology solutions. Our cloud-native, mobile point of service platform empowers retailers to streamline operations, enhance customer experiences, and achieve sustainable growth. With a future-proof architecture and a focus on delivering exceptional value to our clients, Jumpmind is committed to shaping the future of retail technology. Jumpmind powers inspired in-store experiences for a growing list of leading retailers, including American Eagle Outfitters, Build-A-Bear Workshop, DTLR, Petco, Reitmans Canada Ltd., Shoe Palace, The Paper Store, Landmark Group, and The Vitamin Shoppe. Learn more about Jumpmind at www.jumpmind.com.
About Lone View Capital
Lone View Capital is a growth-oriented private equity firm investing across the technology ecosystem. Its team comprises both investors and operators who leverage their deep domain expertise to help exceptional management teams build, transform, and grow market-leading businesses. The firm is based in Los Angeles, CA. For more information about Lone View’s investment strategy and model, visit https://loneviewcap.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250915303895/en/
Contacts
For Lone View Capital:
Parveen Singh, Edelman Smithfield
parveen.singh@edelmansmithfield.com
For Jumpmind:
Erin Lutz, Lutz Public Relations and Marketing
erin@lutzpr.com
949.293.1055
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom